What Are Fake, Counterfeit, and Unregistered GLP-1 Products?

As global demand for GLP-1 receptor agonists (such as semaglutide and liraglutide) and related medicines such as the dual GIP/GLP-1 agonist tirzepatide continues to rise, the market has seen reports of illegal, unverified, and potentially hazardous products. To protect your health, it is critical to understand how public health authorities—such as the World Health Organization (WHO) and the Philippine Food and Drug Administration (FDA)—classify and distinguish these distinct product hazards.

1. Counterfeit or Falsified GLP-1 Products

Definition: Falsified products deliberately and fraudulently misrepresent their identity, composition, or source. Philippine Republic Act No. 8203, the Special Law on Counterfeit Drugs, addresses counterfeit medicines as a criminal offense.

Key Characteristics & Risks:

  • Packaging Imitation: Falsified products may imitate genuine brand-name packaging, logos, batch numbers or injection devices. Even a genuine batch number can appear on a falsified product.
  • Hazardous or Incorrect Ingredients: Falsified products may contain no active ingredient, an incorrect amount, unknown ingredients or harmful contaminants. Their contents cannot be established from packaging or seller claims.
  • Substituted Substances: Regulatory authorities have warned that some potentially fake weight-loss pens may contain insulin instead of the expected medicine. Undeclared insulin can cause severe hypoglycemia (dangerously low blood sugar), which may be life-threatening. This is a reported risk, not a finding about every falsified product.

Source: WHO Medical Product Alert N°2/2024 · Republic Act No. 8203 · MHRA: unsafe fake weight-loss pens (UK safety alert)

2. Substandard GLP-1 Products

Definition: Substandard products, also called out-of-specification products, are authorized medical products that fail to meet their quality standards or specifications. They are distinct from products that deliberately misrepresent their identity or source.

Key Characteristics & Risks:

  • Storage or Transport Problems: GLP-1 medicines have product-specific storage requirements. Incorrect storage or transport can affect quality and potency. Some presentations allow limited room-temperature storage; follow the exact approved label and ask a pharmacist rather than assuming all products need continuous refrigeration.
  • Manufacturing or Stability Deficiencies: Substandard products may suffer from active ingredient under-dosage, improper fill volumes, or contamination introduced during production or packaging.
  • Clinical Impact: A product that fails quality specifications may not work as intended or may cause harm. The risk depends on the specific quality problem; appearance alone cannot establish potency or contamination.

Source: WHO: substandard and falsified medical products

3. Unregistered or Unlicensed GLP-1 Products

Definition: Unregistered or unlicensed medical products have not undergone evaluation or approval by the regulator for the market in which they are supplied. For ordinary commercial sale in the Philippines, check the exact medicine’s valid Philippine FDA registration or Certificate of Product Registration (CPR).

Key Characteristics & Risks:

  • Unverified Claims: A seller’s claim that a product contains authentic or pure semaglutide or tirzepatide does not establish Philippine authorization. Republic Act No. 9711 prohibits commercial activities involving unregistered drug products. Special access, importation or patient-specific circumstances require separate regulatory clarification; do not assume an online offer is permitted.
  • Lack of Local Product Evaluation: An unregistered product has not been evaluated or authorized for the relevant market. Claims about manufacturing, ingredient sourcing, stability or sterility should not be accepted without appropriate verification.
  • Market Vulnerability: Products offered through unidentified sellers or unverified importation channels may be difficult to trace. Verify both the exact product’s registration and the supplying establishment’s authorization.

Source: Republic Act No. 9711

On smaller screens, scroll across to see all columns.

Summary Comparison Table
CategoryPrimary CauseRegulatory/Legal StatusPrimary Risk to Consumer
Counterfeit / FalsifiedIntentional misrepresentation of identity, composition or sourceAddressed by Republic Act No. 8203Incorrect or unknown ingredients, harmful contamination or treatment failure
SubstandardFailure to meet quality specifications, including manufacture, storage or transport problemsAuthorized product that fails quality standardsReduced effectiveness or harm from the specific quality problem
UnregisteredNo evaluation or approval for the relevant marketOrdinary commercial activities involving unregistered drugs are prohibited under RA 9711Unverified local authorization and product-specific quality/safety information

What Are the Warning Signs of Fake or Counterfeit GLP-1 Products?

Falsified prescription products can closely imitate authentic branding. Physical discrepancies may raise concerns, but visual inspection cannot authenticate a medicine.

WHO’s alert on specific falsified Ozempic® products identifies several possible warning signs. Use these examples alongside the exact product’s approved information—not as universal rules for every GLP-1 medicine:

1. Dosing Mechanism and Pen Construction

  • Dose Scale Extension: WHO reported that the specific falsified Ozempic® pens in its 2024 alert may have a scale extending out from the pen when setting the dose. This observation is specific to those devices and should not be used as a universal test for other products.
  • Device or Presentation Differences: Legitimate medicines can be supplied as multi-dose pens, single-dose pens, vials, prefilled syringes or tablets, depending on the product and market. A vial or syringe alone does not prove counterfeiting. Be cautious if the presentation, labeling or instructions do not match the exact authorized product or your prescription; ask a pharmacist to check.

2. Packaging and Labeling Quality

  • Poor Printing and Typos: Counterfeit cartons often feature misspellings, poor color alignment, blurry fonts, or low-grade cardboard.
  • Label Adherence: Labels on counterfeit pens may appear crooked, peel off easily, or lack smooth finish quality.
  • Mismatched Product Details: Compare the lot or batch number, expiry date and any serial number shown on the outer packaging and device with the applicable product information. Missing, altered or inconsistent details warrant a pharmacist or manufacturer check. Matching numbers alone do not prove authenticity.

3. Solution Appearance

Follow the exact product’s approved description. Some injectable solutions are clear and colorless, while certain products may be clear and slightly yellow. Do not use a product with unexpected cloudiness, discoloration or particles; ask a pharmacist to assess it. Abnormal appearance can indicate a quality problem but does not, by itself, prove counterfeiting.

Source: WHO: specific falsified Ozempic® warning signs

Red Flags of Unregistered Sellers and Suspicious Online Offers

Counterfeit and unregistered GLP-1 products thrive in informal and unregulated online channels. Recognizing dangerous purchasing environments helps you stop fraud before it reaches your home.

Red Flag 1: No Prescription Required

Semaglutide, tirzepatide and other prescription GLP-1 medicines should be obtained through the appropriate prescription and licensed dispensing process. An offer to bypass the required prescription is an important warning sign; verify the pharmacy and consult its licensed pharmacist.

Red Flag 2: Significantly Below-Market Prices ("Too Good to Be True")

Is an extremely cheap GLP-1 product a warning sign? Yes. A price far below established pharmacy prices without a credible explanation merits additional checks. A discount, including a promotional offer, does not by itself establish counterfeiting, expiration, smuggling or improper storage.

Red Flag 3: Informal Online Channels and Direct Delivery

Be cautious of sellers operating through:

  • Social media direct messaging or private groups.
  • E-commerce marketplace listings with vague descriptions.
  • Wellness spas or non-medical clinics offering home-delivery "peptide kits."
  • Delivery or packaging that does not meet the exact medicine’s approved storage and transport requirements. Ask the pharmacist whether temperature protection is required for that product and presentation.

What Are the Risks of Using Counterfeit GLP-1 Products?

As part of its mission, AlaGaan: Alagang Ligtas to Live Lighter aims to help Filipinos understand the risks of using fake, counterfeit, substandard, and unregistered GLP-1 products. Knowing these risks can help patients make informed decisions, recognize potential dangers, and seek guidance from qualified healthcare professionals before using these medications.

Using an unverified, falsified or substandard medicine can cause serious harm. Possible risks include:

  • Severe Hypoglycemia: Regulators have warned that some potentially fake weight-loss pens may contain insulin. Unexpected insulin exposure can cause dangerously low blood sugar, including seizures or coma. Seek urgent medical care for severe symptoms.
  • Contamination and Injection Risks: Falsified products may contain unknown ingredients or contaminants. Their sterility may not be assured, creating risks of infection or other serious harm. The specific contents and risk require regulatory or laboratory investigation.
  • Treatment Failure: A product with no active ingredient or an incorrect amount may not provide the intended treatment and can leave blood sugar uncontrolled. Contact your healthcare professional promptly if you suspect the medicine is not working or is unsuitable.

Through its public information campaign, AlaGaan helps patients understand these risks and recognize the importance of verifying a product’s Philippine FDA registration, obtaining medication through legitimate channels, and consulting a healthcare professional. Packaging alone cannot confirm authenticity, and products marketed online should not be assumed safe simply because they look genuine.

Source: WHO: substandard and falsified medical products · MHRA: unsafe fake weight-loss pens (UK safety alert)

How to Check if a Product Is Registered in the Philippines

Before purchasing or using any medication, take a moment to perform an official regulatory verification.

Check the FDA Verification Portal:

  1. Access the official Philippine FDA Verification Portal.
  2. Go to the Drug Products directory.
  3. Search by brand name (Ozempic®, Wegovy®, Mounjaro®, Rybelsus®, Saxenda®, Victoza®, Trulicity®) or active generic molecule (Semaglutide, Tirzepatide, Liraglutide, Dulaglutide).
  4. Match the exact brand, active ingredient, strength, dosage form, manufacturer or authorization holder, CPR number and validity information to the product offered. Check the supplying establishment’s License to Operate separately. A registration record does not authenticate an individual pack, pen or vial.

FDA Philippines’ guidance encourages consumers to use the Verification Portal to check registered products and licensed establishments. If a record is missing, expired or inconsistent, ask FDA Philippines or a licensed pharmacist for clarification before purchasing or using the product.

Check FDA product registration

Action Protocol: What Should You Do If You Suspect a Fake GLP-1 Product?

If you suspect that a product you purchased is fake, counterfeit, or unregistered, follow these immediate safety steps:

  • Stop Using the Product Immediately: Do not inject or consume any remaining medication.
  • Preserve the Product and Packaging: Keep the outer carton, pen device, leaflets, purchase receipts, and seller communication intact. Do not discard them, as they serve as vital evidence.

Report to Regulatory Authorities:

  • General Inquiries: Contact info@fda.gov.ph for general FDA inquiries. Submit covered complaints about suspected counterfeit, unregistered or misbranded products through eSumbong; the former eReport scheme and its reporting emails have been decommissioned.
  • Online Reporting: Submit a report via the official FDA e-Sumbong Portal.
  • Adverse Event Reporting: If you experienced an unexpected side effect or illness, follow the FDA patient pharmacovigilance guidance to report it. Reporting does not replace medical care.

Seek Immediate Medical Attention: Consult a licensed physician or visit a healthcare facility right away if you experience unusual symptoms such as extreme dizziness, sweating, confusion, vomiting, or signs of infection.

Report to FDA Philippines

How AlaGaan Can Help You Report Suspicious Products or Sellers

As part of its Alagang Ligtas to Live Lighter advocacy, AlaGaan helps Filipinos understand the risks of fake, counterfeit, and unregistered GLP-1 medications and encourages consumers to report suspicious products and sellers.

If you encounter a product you suspect is fake, counterfeit, or unregistered, or a seller making questionable claims about its authenticity or regulatory approval, you can email report@alagaan.org for assistance with reporting the concern.

To help facilitate the review of your report, include as much of the following information as possible:

  • Product details: Brand name, active ingredient, dosage or strength, dosage form, batch or lot number, and expiration date, if available.
  • Seller information: Seller's name, business name, contact details, website, social media account, online marketplace listing, or physical store address.
  • Purchase details: Date and place of purchase, price paid, and order or transaction number, if applicable.
  • Registration concerns: The product's CPR number, if shown, and the results of your FDA Verification Portal search. Explain what appears inconsistent or could not be verified.
  • Supporting evidence: Clear photos of the packaging, labels, product, and receipt, as well as screenshots of advertisements, product listings, seller conversations, or other relevant claims.
  • Description of the concern: Explain why you suspect the product or seller may be fraudulent, counterfeit, or unregistered. Include any unusual packaging, suspicious claims, or discrepancies you observed.
  • Adverse reactions, if any: Describe any suspected side effects or health problems associated with the product, including when they occurred. Do not include unnecessary personal or sensitive medical information in your initial email.

Frequently Asked Questions (FAQs)

What are the differences between counterfeit, substandard, and unregistered GLP-1 weight loss products?

Falsified or counterfeit products deliberately misrepresent their identity, composition or source. Substandard products are authorized products that fail quality standards or specifications. Unregistered products have not been evaluated or approved for the market in which they are supplied. These categories are distinct: lack of local registration does not, by itself, prove that a product is falsified.

How can I identify fake GLP-1 weight loss products?

Look for unexpected packaging or labeling errors, altered or inconsistent product details, and a device or solution that does not match the exact approved product information. WHO’s extended dose-scale example concerns specific falsified Ozempic® pens, not all GLP-1 products. Packaging, a vial or syringe presentation, or appearance alone cannot establish authenticity; ask a pharmacist for help.

What are the warning signs of counterfeit Ozempic® or Mounjaro®?

Warning signs include an offer to bypass a required prescription, an unexplained unusually low price, inconsistent packaging details, or handling that does not meet the exact product’s storage instructions. These are reasons to verify the source—not proof that every such product is counterfeit.

How can I tell if a GLP-1 product is unregistered?

Search the exact brand, active ingredient, strength and dosage form in the FDA Philippines Verification Portal and review the CPR information and validity. Check the supplying establishment’s license separately. If the record is missing or does not match, ask FDA Philippines or a licensed pharmacist to clarify; a failed search alone is not conclusive proof of the product’s status.

Is a very cheap GLP-1 product a warning sign?

Yes. An unusually low price without a credible explanation is a reason to pause and check the source, registration, product details and handling. Price alone does not confirm counterfeiting or any particular quality problem.

How do I report fake medicine in the Philippines?

Report suspected products or sellers through FDA Philippines’ official eSumbong channel or its published reporting contacts. If you suspect an adverse reaction, use the FDA’s official adverse-event reporting guidance and seek medical advice; reporting does not replace urgent care.

Sources and Further Reading

International safety alerts and U.S. product labels provide product-specific examples; they do not establish Philippine registration or local availability. Follow the exact locally authorized product information and ask a licensed pharmacist or FDA Philippines when details are unclear.

Stay Informed With AlaGaan: Alagang Ligtas to Live Lighter

Making informed decisions about GLP-1 medications starts with reliable information, appropriate medical guidance, and careful verification of the products you use.

AlaGaan: Alagang Ligtas to Live Lighter is committed to helping patients and the public better understand GLP-1 medications, recognize potential safety risks, and make informed decisions about their health. Through accessible educational resources, the campaign encourages everyone to ask questions, verify product claims, and work with qualified healthcare professionals.

Take the next step toward safer, more informed health decisions:

Be part of a more informed community. Stay connected with AlaGaan and make your health decisions with reliable information.

AlaGaan is an educational public health campaign, not a pharmacy or clinical provider. It does not replace professional medical advice, diagnosis, or treatment.

Explore AlaGaan articlesAsk a Doctor